e-learning
resources
Munich 2014
Wednesday, 10.09.2014
Lung function, COPD and inflammation
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
COPD exacerbations occur more frequently in the presence of cardiovascular and pulmonary comorbidities and increase serum lipids
D. Jungck, S. Blum, I. Isbruch, J. Knobloch, A. Koch (Bochum, Germany)
Source:
International Congress 2014 – Lung function, COPD and inflammation
Session:
Lung function, COPD and inflammation
Session type:
Poster Discussion
Number:
4761
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Jungck, S. Blum, I. Isbruch, J. Knobloch, A. Koch (Bochum, Germany). COPD exacerbations occur more frequently in the presence of cardiovascular and pulmonary comorbidities and increase serum lipids. Eur Respir J 2014; 44: Suppl. 58, 4761
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Cardiovascular risk assessment in COPD patients with severe exacerbation
Source: International Congress 2016 – Comorbidities and exacerbations in COPD
Year: 2016
Prevalence of exacerbation in COPD patients with chronic bronchitis and association with elevated serum inflammatory biomarkers
Source: International Congress 2014 – Systemic biomarkers for airway diseases
Year: 2014
Cardiovascular risk, subclinical atherosclerosis and markers of systemic inflammation in patients with COPD and frequent exacerbator phenotype
Source: International Congress 2016 – Monitoring comorbidities
Year: 2016
Medical and demographic loss of population due to chronic obstructive pulmonary disease
Source: International Congress 2016 – Screening, diagnosis, assessment, and treatment of COPD in primary care
Year: 2016
Comorbidities in patients with COPD and their impact on COPD course
Source: International Congress 2014 – Prevalence of COPD and mortality from COPD
Year: 2014
Cardiovascular comorbidities of COPD in never-smokers
Source: International Congress 2014 – Highlights in respiratory epidemiology
Year: 2014
Chronic obstructive pulmonary disease and sudden cardiac death: The Rotterdam study
Source: International Congress 2015 – COPD and lung function: risk factors and outcomes
Year: 2015
Relation of American Heart Association’s life’s simple 7 cardiovascular health factors with chronic obstructive pulmonary disease
Source: International Congress 2016 – Comorbidities and exacerbations in COPD
Year: 2016
Cardiovascular status of patients with a severe form of COPD
Source: International Congress 2015 – Diagnosing and management of COPD in primary care
Year: 2015
Characteristics and consequences of chronic obstructive pulmonary disease in never smokers
Source: Annual Congress 2013 –Investigating COPD in longitudinal studies
Year: 2013
Risk of cardiovascular comorbidities in patients with idiopathic pulmonary fibrosis: Analysis of Medicare data
Source: International Congress 2016 – Burden of respiratory diseases: from environmental aspects to healthcare consumption
Year: 2016
The frequency of COPD exacerbations is related to the comorbidity profile
Source: International Congress 2016 – Comorbidities and exacerbations in COPD
Year: 2016
The prevalence of co-morbidities and exacerbations in COPD patients in Slovenia
Source: International Congress 2015 – Risk factors and co-morbidities in asthma and COPD
Year: 2015
Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease
Source: Annual Congress 2013 –Investigating COPD in longitudinal studies
Year: 2013
Inflammatory markers and COPD phenotypes as predictors of COPD exacerbations
Source: Annual Congress 2013 –Investigating COPD in longitudinal studies
Year: 2013
Impact of not planned readmissions due to acute exacerbations of chronic obstructive pulmonary disease
Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD
Year: 2015
Predictors of exacerbation frequency in chronic obstructive pulmonary disease
Source: International Congress 2015 – Asthma and COPD: overlap and exacerbations
Year: 2015
Clinical features of chronic obstructive pulmonary disease in never smokers
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016
COPDCoRi, an algorithm for predicting the risk of coronaropathy in COPD patients
Source: International Congress 2014 – Prevalence of COPD and mortality from COPD
Year: 2014
Distribution of blood eosinophil in COPD patients
Source: International Congress 2014 – Lung function, COPD and inflammation
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept